Immuneering Announces $30 Million Underwritten Offering
April 18 2023 - 9:24AM
Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a
clinical-stage oncology company developing medicines for broad
populations of cancer patients with an initial aim to develop a
universal-RAS therapy, today announced the pricing of its
underwritten offering of 2,727,273 shares of its Class A common
stock at an offering price of $11.00 per share. The gross proceeds
from the offering are expected be $30 million, before deducting
underwriting discounts and commissions and estimated offering
expenses payable by Immuneering. All shares in the offering will be
offered by Immuneering.
Jefferies, TD Cowen and Guggenheim Securities
are acting as the joint book-running managers for the offering.
Immuneering intends to use the net proceeds of
the offering to advance the preclinical and clinical development of
its product candidates and for working capital and other general
corporate purposes.
The offering is being made pursuant to a shelf
registration statement on Form S-3, including a base prospectus,
that was filed by Immuneering with the Securities and Exchange
Commission (the “SEC”) on August 10, 2022 and declared effective by
the SEC on August 19, 2022. A preliminary prospectus supplement
relating to the offering was filed with the SEC on April 18, 2023.
The final prospectus supplement relating to the offering will be
filed with the SEC. Copies of the final prospectus supplement
relating to the offering, when available, may be obtained from:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by telephone at (877)
821-7388 or by e-mail at prospectus_department@jefferies.com; Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by
email at Prospectus_ECM@cowen.com or by telephone at (833)
297-2926; or Guggenheim Securities, LLC, Attention: Equity
Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New
York 10017 or by visiting the EDGAR database on the SEC’s website
at www.sec.gov.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Forward Looking Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the consummation of the offering, the terms of
the offering, the anticipated use of the net proceeds from the
offering and the anticipated gross proceeds therefrom. Statements
using words such as “expect”, “anticipate”, “believe”, “may”,
“will” and similar terms are also forward-looking statements.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements and we
caution investors not to place undue reliance on the
forward-looking statements contained in this press release. Such
statements are subject to numerous risks and uncertainties,
including, but not limited to, risks associated with general
economic and market conditions and the other important factors
discussed under the caption “Risk Factors” in the prospectus
supplement related to the offering, our Annual Report on Form 10-K
for the year ended December 31, 2022 and our other filings with the
SEC. Except as required by law, we undertake no obligations to make
any revisions to the forward-looking statements contained in this
press release or to update them to reflect events or circumstances
occurring after the date of this press release, whether as a result
of new information, future developments or otherwise.
Corporate Contact:Gina
NugentNugent
Communications617-460-3579gina@nugentcommunications.com
Investor Contact:Laurence
WattsGilmartin Group619-916-7620laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin Group 332-895-3225
kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024